

2012年3月期 第3四半期決算 補足資料 Additional Information for the Third Quarter of the Fiscal Year Ending March 31, 2012

セグメント別売上概況 Net Sales by Business Segment

(百万円: millions of yen)

		Q3 YTD Mar. 2011			Q3 YTD Mar. 2012					
		JPN	Overseas	WW	JPN	%	Overseas	%	WW	%
ホスピタル医療器類	Disposable medical products and Medical electronic products and others	42,231	20,892	63,123	41,423	-1.9%	20,715	-0.8%	62,138	-1.6%
医薬品類	Pharmaceuticals / Nutritious food	39,556	10	39,566	39,166	-1.0%	15	55.6%	39,181	-1.0%
糖尿病事業	Diabetes Care Business	11,641	1,209	12,851	11,116	-4.5%	1,091	-9.8%	12,208	-5.0%
ホスピタル事業	General Hospital Business	93,428	22,112	115,540	91,705	-1.8%	21,822	-1.3%	113,528	-1.7%
カテーテルシステム	Interventional systems	21,524	52,180	73,705	30,697	42.6%	56,447	8.2%	87,144	18.2%
人工心肺システム他	Cardiovascular systems and others	6,736	18,968	25,704	7,164	6.4%	17,309	-8.7%	24,473	-4.8%
人工血管	Vascular grafts	1,528	5,902	7,430	1,580	3.4%	5,472	-7.3%	7,053	-5.1%
心臓血管領域事業	Cardiac & Vascular Business	29,789	77,051	106,840	39,442	32.4%	79,229	2.8%	118,672	11.1%
血液システム事業	Blood Management Business	7,784	10,610	18,394	9,179	17.9%	44,046	315.1%	53,226	189.4%
ヘルスケア事業	Consumer Healthcare Business	2,889	470	3,359	2,927	1.3%	559	18.9%	3,486	3.8%
計	Total	133,891	110,244	244,136	143,255	7.0%	145,658	32.1%	288,914	18.3%

(期中平均為替レート) Average exchange rate (US\$1=¥86.85) (EUR1=¥113.28) (US\$1=¥78.98) (EUR1=¥110.62)

海外子会社の会計期間統一	Accounting Period Adjustment of Overseas Subsidiaries									
海外子会社の会計期間統一	Accounting Period Adjustment of Overseas Subsidiaries	-	105	105	-	-	-	-100.0%	-	-100.0%
合計	TOTAL	133,891	110,349	244,241	143,255	7.0%	145,658	32.0%	288,914	18.3%

四半期別推移 Quarterly History for the Income Statement

		Q1	Q2	Q3	Q4	Mar. 2011	Q1	Q2	Q3	Q4	Mar. 2012	Mar. 2012
		Mar. 2011	Mar. 2011	Mar. 2011	Mar. 2011		Mar. 2012	Mar. 2012	Mar. 2012	Mar. 2012	Forecast	Forecast
売上高	Net Sales	81,234	82,684	80,322	83,973	328,214	95,630	95,088	98,195	94,085	383,000	
	各四半期売上高/年間売上高	24.8%	25.2%	24.5%	25.5%	100.0%	25.0%	24.8%	25.6%	24.6%	100.0%	
売上総利益	Gross Profit	42,336	43,263	41,564	43,634	170,798	50,842	52,334	50,812			
	%/Net Sale	52.1%	52.3%	51.7%	52.0%	52.0%	53.2%	55.0%	51.7%			
販売管理費	SG&A Expenses	26,389	26,503	26,171	29,127	108,191	33,463	35,080	35,570			
	%/Net Sale	32.5%	32.1%	32.5%	34.7%	32.9%	35.0%	36.9%	36.2%			
営業利益	Operating Income	15,946	16,760	15,393	14,506	62,606	17,378	17,254	15,242	12,724	62,600	
	%/Net Sale	19.6%	20.3%	19.2%	17.3%	19.1%	18.2%	18.1%	15.5%	13.5%	16.3%	
経常利益	Ordinary Income	12,554	15,620	14,720	14,008	56,903	16,868	14,423	15,027	10,680	57,000	
	%/Net Sale	15.5%	18.9%	18.3%	16.7%	17.3%	17.6%	15.2%	15.3%	11.4%	14.9%	
当期純利益	Net Income	8,792	9,571	9,118	4,856	32,338	9,772	7,940	4,250	4,037	26,000	
	%/Net Sale	10.8%	11.6%	11.4%	5.8%	9.9%	10.2%	8.4%	4.3%	4.3%	6.8%	

キャッシュ・フロー計算書 (要約) Statements of Cash Flows

	Q3 YTD	Q3 YTD	
	Mar. 2011	Mar. 2012	
営業キャッシュ・フロー	Net Cash Provided by (Used in) Operating Activities	25,757	35,981
投資キャッシュ・フロー	Net Cash Provided by (Used in) Investing Activities	△13,625	△235,908
フリーキャッシュ・フロー	Free Cash Flow	12,132	△199,926
財務キャッシュ・フロー	Net Cash Provided by (Used in) Financing Activities	△26,311	193,082
現金同等物の換算差額	Effect of exchange rate change on cash and cash equivalents	△5,245	△2,724
現金及び現金同等物の増減	Net increase (decrease) in cash and cash equivalents	△19,425	△9,568
現金及び現金同等物の期首残高	Cash and cash equivalents at beginning of period	84,877	82,660
現金及び現金同等物の四半期末残高	Cash and cash equivalents at end of period	65,452	73,091

参考情報 Additional Information

	Q3 YTD	Q3 YTD	Mar. 2012	
	Mar. 2011	Mar. 2012	Forecast	
研究開発費	Research and Development	14,460	17,624	23,000
設備投資額	Capital Expenditure	14,117	17,806	28,500
減価償却費	Depreciation and Amortization	14,724	21,436	*a 30,000

\*a 有形固定資産の償却方法を定率法から定額法へ変更したことによる影響想定額 △4,600百万円を含んでおります。